Global Infertility Treatment Market Overview:
According to SPER Market Research, the global infertility treatment market was valued at USD 1.7 Bn in 2021 and estimated to reach USD 2.9 Bn by 2030 with a CAGR of 8.5%. The fertility rates across the world are declining. The global total fertility rate per women in 2020 was 2.3 which is lower than 3.2 which it used to be in 1990. The dropping global total fertility rates is primarily driving the global infertility treatment market in the forecast period.
Impact of COVID-19 on the Infertility Treatment Market
COVID-19 has negatively impacted the infertility treatment market in the forecast period. During the pandemic, plethora of challenges are observed such as prioritizing the treatment for COVID patients, exposure of healthcare providers to the COVID-19 infection, logistic issues, shortage of equipment. For any infertility treatment, in-person appointments are required which are restricted during the pandemic. The patients also try to avoid the healthcare settings during the upsurge in COVID-19 infections leading to cancellation or postponement of infertility treatments.
Scope of the report:
| Report Metric | Details |
| Market size available for years | 2019-2030 |
| Base year considered | 2021 |
| Forecast period | 2022-2030 |
| Segments covered | By Product, By Procedure, By Patient Type, By End User |
| Geographies covered | North America, Europe, APAC, Latin America, and the Middle East & Africa |
| Companies Covered | Cook Group, DxNow, Inc., Esco Micro Pte. Ltd., FUJIFILM Irvine Scientific, Genea Biomedx, Gynotec B.V., Hamilton Thorne Ltd., IHMedical A/S, InVitroCare Inc., IVFtech ApS, Kitazato Corporation, MedGyn Products, Inc., Nidacon International AB, Rocket Medical plc, SAR Healthline Pvt. Ltd., The Baker Company, Inc., The Cooper Companies Inc., Thermo Fisher Scientific, Inc., Vitrolife, ZEISS Group |
Driver: Declining fertility rate
The global fertility rates are declining due to late marriages and age-related factors. This creates a driving force for this market. The global fertility rates are expected to further decrease to 2.0 by 2050. The infertility treatment options help in determining the fertile window in males and females and conceive using various assisted reproductive techniques.
Challenge: Barriers for Assisted reproductive technology
The adoption of assisted reproductive technology is restricted by the pre conceived notions on various ethical, societal and legal issues. Economic barrier associated with infertility treatments is also a significant challenge for the growth of this market.
Opportunity: Emerging economies of Asia
Emerging economies such as China, India in Asia-Pacific will provide growth opportunities to this market. The growth is mainly projected in theses countries due to rapidly developing healthcare infrastructure, medical tourism, increasing healthcare expenditure and partnerships of leading players of this market with domestic players in these countries.
Infertility Treatment Market Segmentation:
By Product: Based on product, market has been segmented into Equipment (Microscopes, Imaging Systems, Incubators, Cryosystems, Sperm Separation Devices), Media & Consumables and Accessories.
By Procedure: Based on procedure, the market is segmented into Assisted reproductive Technology, Artificial Insemination, Fertility Surgeries and Other infertility treatment procedures.
By Patient Type: Based on Patient type, the market is segmented into female infertility treatment, male infertility treatment.
By End User: Based on End User, the market is segmented into fertility centers, hospitals & surgical clinics, cryobanks, research institutes
By Region: Asia-Pacific owns the largest share of this market due to rise in medical tourism, rapidly evolving healthcare infrastructure, growing awareness, increasing healthcare expenditure and penetration of leading players through partnerships with domestic players.
1. Introduction
2. Research Methodology
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. COVID-19 Impact of the Infertility Treatment Market
4.4. Market Trends
5. Global Infertility Treatment Market, By Product, 2021-2030 (USD Million)
5.1. Equipment
5.1.1. Microscopes
5.1.2. Imaging Systems
5.1.3. Sperm Analyzer Systems
5.1.4. Ovum Aspiration Pumps
5.1.5. Micromanipulator Systems
5.1.6. Incubators
5.1.7. Gas Analyzers
5.1.8. Laser Systems
5.1.9. Cryosystems
5.1.10. Sperm Separation Devices
5.2. Media & Consumables
5.3. Accessories
6. Global Infertility Treatment Market, By Procedure, 2021-2030 (USD Million)
6.1. Assisted Reproductive Technology
6.1.1. In Vitro Fertilization
6.1.1.1. Intracytoplasmic Morphologically Selected Sperm Injection
6.1.1.2. Gamete Donation
6.1.2. Intracytoplasmic Sperm Injection
6.1.3. Surrogacy
6.2. Artificial Insemination
6.2.1. Intrauterine Insemination
6.2.2. Intracervical Insemination
6.2.3. Intratubal Insemination
6.3. Fertility Surgeries
6.3.1. Laparoscopy
6.3.2. Hysteroscopy
6.3.3. Myomectomy
6.3.4. Laparotomy
6.3.5. Tubal Ligation Reversal
6.3.6. Varicocelectomy
6.3.7. Microsurgical Reconstruction
6.3.7.1. Vasovasostomy
6.3.7.2. Vasoepididymostomy
6.4. Other Infertility Treatment Procedures
7. Global Infertility Treatment Market, By Patient, 2021-2030 (USD Million)
7.1. Female Infertility Treatment
7.2. Male Infertility Treatment
8. Global Infertility Treatment Market, By End User, 2021-2030 (USD Million)
8.1. Fertility Centers
8.2. Hospitals & Surgical Clinics
8.3. Cryobanks
8.4. Research Institutes
9. Global Infertility Treatment Market, By Geography, 2021-2030 (USD Million)
9.1. North America
9.1.1. US
9.1.2. Canada
9.2. Europe
9.2.1. Germany
9.2.2. UK
9.2.3. France
9.2.4. Italy
9.2.5. Spain
9.2.6. Rest of Europe
9.3. Asia-Pacific
9.3.1. China
9.3.2. Japan
9.3.3. India
9.3.4. Rest of Asia-Pacific
9.4. Rest of the World
9.4.1. Latin America
9.4.2. Middle East & Africa
10. Competitive Landscape
10.1. Introduction
10.2. Market Share Analysis, By Key Players (2021)
10.3. Competitive Scenario
10.3.1. Product Launches
10.3.2. Partnerships, Collaborations and Agreements
10.3.3. Acquisitions
10.3.4. Expansions
10.3.5. Other Developments
11. Company Profiles
11.1. Cook Group
11.2. DxNow, Inc.
11.3. Esco Micro Pte. Ltd.
11.4. FUJIFILM Irvine Scientific
11.5. Genea Biomedx
11.6. Gynotec B.V.
11.7. Hamilton Thorne Ltd.
11.8. IHMedical A/S
11.9. InVitroCare Inc.
11.10. IVFtech ApS
11.11. Kitazato Corporation
11.12. MedGyn Products, Inc.
11.13. Nidacon International AB
11.14. Rocket Medical plc
11.15. SAR Healthline Pvt. Ltd.
11.16. The Baker Company, Inc.
11.17. The Cooper Companies Inc.
11.18. Thermo Fisher Scientific, Inc.
11.19. Vitrolife
11.20. ZEISS Group
12. Appendix
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
